As previously reported, Leerink downgraded Dentsply Sirona (XRAY) to Market Perform from Outperform with a price target of $21, down from $32, citing Q3 results and “a number of ongoing uncertainties on the full growth profile.” The firm, which says it is “admittedly late on this” call, cites the lower visibility on revenue growth, the pull-through dynamics into the next few years, and the pathway to returning to normalized growth, as well as a lack of details on the announced investigation in Germany that management disclosed on the call, which it contends “at a minimum can serve as a near-term overhang on the stock.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XRAY:
- Dentsply Sirona downgraded to Market Perform from Outperform at Leerink
- DENTSPLY SIRONA Revises Outlook Amid Goodwill Impairments
- Dentsply Sirona reports Q3 adjusted EPS 50c, consensus 47c
- Dentsply Sirona lowers FY24 adj EPS view to $1.82-$1.86 from $1.96-$2.02
- XRAY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
